A major breakthrough in mRNA oncology therapy! JD Health (06618) and Likang Life Science signed a strategic cooperation agreement

The Zhitong Finance App learned that on September 2, JD Health (06618) and Licang Life Technology reached a strategic cooperation. The two sides will focus on innovative directions of precise immunotherapy for tumors such as personalized mRNA tumor vaccines, focusing on cooperation in patient services, medical collaboration, clinical research subject recruitment, and high-end health management services. As the first stop for the launch of new specialty drugs, the two sides will provide launch support for new cancer vaccine products, and jointly promote a more efficient and standardized connection between cutting-edge technology, medical services and patient needs.

Since this year, important progress has been made in personalized neoantigen mRNA oncology therapy. Recently, Moderna participated in the development of personalized novel antigen mRNA therapy combined with immunotherapy, and obtained positive phase III clinical study results for the first time in the world, indicating that the clinical value of precise immunotherapy for tumors is being further verified. The technology analyzes patient-specific tumor mutations through genetic sequencing, combines artificial intelligence to screen potential novel antigens, and realizes personalized drug design and preparation based on mRNA technology, thereby stimulating an accurate immune response to patients' unique tumor characteristics. As a cutting-edge direction for the deep integration of precision medicine and tumor immunotherapy, it is expected to provide more personalized and precise treatment options for cancer patients, and is becoming an important breakthrough direction for innovative cancer treatment around the world.

The product LK101 being developed by Likang Life Technology is in the same direction as the international similar products mentioned above, in the same direction as personalized neoantigen mRNA tumor immunotherapy, but it uses different technical paths in mRNA delivery and immune activation methods. LK101 uses the mRNA-DC technology route to transfect mRNA encoding tumor neoantigen into the patient's own dendritic cells (DC) in vitro and return it to the patient's body to activate specific T cells and trigger an immune response to the patient's personalized tumor targets. Currently, LK101 is the first personalized mRNA tumor vaccine to obtain drug clinical trial approval in China, and obtained US FDA clinical trial approval in 2025, and has now entered phase II clinical research.

In this cooperation, JD Health will utilize its comprehensive capabilities in pharmaceutical supply chains, internet medical care, patient services, and online and offline medical resource collaboration; Likang Life Technology will rely on its technical accumulation in the discovery of novel tumor antigens, personalized mRNA design and preparation, and precise immunotherapy product development to promote a more efficient connection between cutting-edge innovative therapies and medical services, patient needs and industrial resources.

The head of the JD Health and Pharmaceutical business said that cancer treatment is entering a stage of more accurate and personalized development. From research and development to patients, innovative treatments require joint support from platforms, medical resources, and service systems. JD Health hopes to use their respective advantages with Likang Life Technology to promote a better connection between cutting-edge technology and patient services, so that more patients can obtain high-quality health services in a convenient and standardized manner.

Chen Li, CEO of Likang Life Technology, said that Likang Life Technology has always focused on the development of innovative drugs for precise immunotherapy of tumors, and is committed to exploring more accurate treatment plans for cancer patients through AI-driven personalized antigen diagnosis platforms, mRNA technology platforms, and cell production platforms. The strategic cooperation reached with JD Health will help the two sides strengthen collaboration on LK101 related clinical research and future patient service system construction, and promote clinical research and subsequent transformation of innovative results in a more standardized and efficient manner.

In the future, the two sides will jointly explore more standardized and efficient access methods in terms of recruitment of clinical research subjects, improve the efficiency of matching between clinical research and suitable populations, and support the promotion of innovative therapy research. In terms of innovative drug marketing and launch cooperation, the two sides will make full use of JD Health's resources in patient education, pharmaceutical services, supply assurance, and commercial operation to provide users with relevant needs with compliant health science, demand identification, consulting services and medical service connections, and explore full-process collaboration from product information transmission to drug use service support. At the same time, the two sides will also combine JD Health's offline high-end health management service scenario to study more possibilities for the introduction of innovative therapies, clinical transformation, and long-term patient services.

Using this cooperation as a starting point, JD Health and Likang Life Technology will continue to deepen collaboration in the field of innovative cancer treatment, promote the integrated development of scientific research, medical services and industrial resources, and bring more diverse and accessible health service choices to cancer patients.